Non-HDL C equals apolipoprotein B: Except when it does not!

Current Opinion in Lipidology

Volumn 21, Issue 6, 2010, Pages 518-524

  Sniderman, Allan ^a   Williams, Ken ^b   De Graaf, Jacqueline ^c  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

apolipoprotein B; cardiovascular risk; LDL C; non HDL C

Indexed keywords

APOLIPOPROTEIN B; BIOLOGICAL MARKER; CHOLESTEROL ESTER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DYSLIPOPROTEINEMIA; HUMAN; MEDICAL LITERATURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK; THERAPY EFFECT;

APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CANADA; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; CLINICAL TRIALS AS TOPIC; DIAGNOSIS, DIFFERENTIAL; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; INDIVIDUALIZED MEDICINE; LIPID METABOLISM; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 78650304332     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32833ee80c     Document Type: Review

References (17)

1. Erqou S, Kaptoge S, Perry PL, et al., Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke and nonvascular mortality. J Am Med Assoc 2009; 302:412-423.
2. Sniderman AD, McQueen M, Contois J, et al. Why is nonhigh-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol? J Clin Lipidology 2010; 4:152-155.
3. Sniderman AD, Couture P, de Graaf J. Diagnosis and treatment of the apoB dyslipoproteinemias. Nature Clin Endocrinol Metab 2010; 6:335-346.
4. Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. J Am Med Assoc 2007; 298:776-785.
5. Veniant MM, Withycombe S, Young SG. Lipoprotein size and atherosclerosis susceptibility in Apoe -/- and Ldlr -/- mice. ATVB 2001; 21:1567-1570.
6. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and risk of coronary heart disease: 10158 incident cases among 262 525 participants in 29 western prospective studies. Circulation 2007; 115:450-458.
7. Sarwar N, Danesh J, Triglyceride Coronary Disease Genetics Consortium, Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010; 375:1634-1639.
8. Sniderman AD, de Graff J, Couture P. ApoB and the atherogenic ApoB dyslipoproteinemias. In: Kwiterovich Jr PO, editor. The Johns Hopkins text book of dyslipidemia. Philadelphia, PA: Lippincott Williams & Wilkins; 2009. pp. 196-210.
9. Sniderman AD, Williams K, McQueen MJ, Furberg CD. When is equal not equal? J Clin Lipidol 2010; 4:83-88.
10. Sniderman AD, Tremblay A, Bergeron J, et al. Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B. J Clin Lipidol 2007; 1:256-263.
11. Cromwell WC, Otvos JD, Keyes MJ, et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study - implications for LDL management. J Clin Lipidol 2007; 1:583-592.
12. Kastelein JP, Van der Steeg WA, Holme I, et al., for the TNT and IDEAL Study Groups. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008; 117:3002-3009.
13. Sniderman AD, Kiss R. The strengths and limitations of the ApoB/ApoA-1 ratio to predict the risk of vascular disease: a Hegelian analysis. Curr Atherosclerosis Rep 2007; 9:261-265.
14. Keech A, Simes RJ, Barter P, et al., FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Erratum in: Lancet 2006; 366:1415 and 1520. Lancet 2005; 366:1849-1861.
15. Ginsberg HN, Elam MB, Lovato LC, et al., ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563-1574.
16. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009; 25:567-579.
17. Ridker PM, Danielson E, Fonseca FA, et al., JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.